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OBJECTIVES: Basosquamous carcinoma (BSC) is a rare tumor entity, and the most common onset is in the head
and neck region (BSC-HN). The data on diagnosis, treatment, and especially risk assessment concerning disease
course and outcome are deficient or inconsistent. This study aimed to evaluate risk factors for local relapse (LR)
and lymph node metastasis (LNM) and their impact on progression-free survival (PFS). MATERIALS AND
METHODS: In a retrospective monocentric study, patients with BSC-HN treated between 1999 and 2011 were
analyzed regarding clinical and histologic characteristics. Prognostic parameters for LR, LNM, and PFS were
evaluated. In total, 89 patients (55 male, 34 female, mean age of 71.8 years) with a mean follow-up time of 47.7
months (range 12-112) were included. RESULTS: LR occurred in four patients (4.5%), LNM occurred in five patients
(5.6%). Patients with LNM had a significantly shorter PFS time (16.1 months) compared with patients without LNM
(154.2 months; P b .001). Tumor depth and size (T classification), incomplete resection, localization at the ear,
deep maximal vertical infiltration, muscle and vessel invasion all showed significant (P b .05) associations with LR,
LNM, and shorter PFS time. BSC showed more histologic features of basal cell carcinoma (BCC), especially with
regard to BerEP4 expression. CONCLUSION: While histology shows some typical characteristics of BCC, the
biologic behavior and aggressiveness of BSC are similar to those of cutaneous squamous cell carcinoma. This is
the first study to show that LR and, especially, LNM indicate a higher risk of an unfavorable outcome.
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Basosquamous carcinoma (BSC) is an uncommon skin cancer entity.
As a rare variant or subtype of basal cell carcinoma (BCC), it features
characteristics of both BCC (especially histologic characteristics) and
squamous cell carcinoma (SCC; mainly clinical behavior) [1–5]. First
described by MacCormac in 1910 [6], BSC is a rare tumor with an
incidence of less than 2% of all non-melanoma skin cancers and is
predominant in men [5,7–9]. Its etiology is multifactorial, but UV
radiation, aging, and tobacco exposure seem to play key roles in the
onset of BSC [1,5,10,11]. BSCs mainly occur in older Caucasian
males and are usually located in the head and neck area (BSC-HN) or
in other sun-exposed areas [5,7,12]. In addition, rare cases have also
been detected in the upper aerodigestive tract, such as the base of the
tongue, hypopharynx and larynx, and in less common sites of origin,
Figure 1. Histologic characteristics of BSC. In conventional
histology (A; HE, ×400), BSC shows nuclear pleomorphia, with
many mitotic cells showing atypical mitosis, and a loss of
palisades, which are usually typical for BCC. Immunohistochemical
staining with BerEP4 (B; BerEP4, ×100) illustrates irregular mixture
of BCC-typical areas (red) and dedifferentiated areas with more
similarities to SCC. Conventional histology of the same tumor
(C; HE, ×100) depicts the aforementioned BSC characteristics.
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simulate BCCs clinically and morphologically, but BSC-HN is more
aggressive and metastasizes in up to 17.9% of cases [2,7,17–19].
BSC-HN appearance can vary and can include BCC signs (e.g.,
telangiectasia) or SCC characteristics or can appear as a palpable mass
with or without ulceration. The symptoms of BSC-HN are not
specific and depend on tumor location [1,5,20–22]. The histogenesis
of BSC-HN is not yet clear, but it is thought that the tumor originates
from totipotent cells in the basal layer [2,3,23].
Standard therapy for BSC-HN includes Mohs micrographic
surgery with wider excision margins than for BCC or SCC, and
careful follow-up is obligatory [8,19,24]. Concerning dissemina-
tion and risk factors for nodal and distant metastasis (DM) in BSC,
in general, and BSC-HN, especially, data are insufficient.
Therefore, the need for lymph node management in BSC-HN
has not been sufficiently elucidated previously. To date, it is
unclear to what extent clinical or histologic parameters can aid in
risk assessment in BSC-HN.
The purpose of this study was to analyze characteristics and
outcomes in patients with BSC-HN and to evaluate which variables
may be useful for prognostication of local recurrence, nodal
dissemination, and progression-free survival (PFS).
Material and Methods
Patients
Patients treated between 1999 and 2011 for BSC in the head and
neck region (BSC-HN) were identified in a retrospective manner
from our institutional database. Correct classification as histologically
proven BSC was confirmed by the histologic analysis described below.
Only patients with a minimum follow-up of 12 months were
included in this study. Tumor excision was performed using strictly
histographic surgery in all operated cases. This study included 89
patients with BSC-HN (55 male and 34 female, ratio 1.6:1).
The local ethics committee (Ethical Committee of the Westphalian
Wilhelms-University, Münster, Germany; Approval No. 2014-528-
f-S) approved this study. The study was conducted in accordance with
the Guidelines for Good Clinical Practice and in compliance with the
Declaration of Helsinki. Patients gave written informed consent for
the analysis of their data and tumor specimens.
Histologic Analysis
A tumor biopsy was cut into 2- to 4-μm sections after being fixed
in formalin and embedded in paraffin. In addition to hematoxylin/
eosin (HE) staining, immunohistochemistry was performed using
standard immunoperoxidase techniques. The sections were dewaxed
in xylol (Merck, Darmstadt, Germany) and rehydrated in serial
dilutions of ethanol. The DAKO autostainer was used in
combination with the Chem-Mate Detection Kit by DAKO
(LSAB-KIT, DAKO, Hamburg, Germany). All biopsies were
reviewed independently by two experts in dermatopathology (C.H.
and H.-J.S.). Histopathologic pictures were captured with a Zeiss
Axioskop 2 plus microscope using a Zeiss Axiocam HRC camera
(Zeiss, Jena, Germany)
We used the following strict histologic criteria for the diagnosis of
BSC: loss of BerEP4 staining in portions of the tumor, loss of
palisading, increased nuclear atypia, significant squamous differenti-
ation, and loss of basaloid cytology in portions of the tumor
(Figure 1). We excluded patients with composite tumors of SCC and
BCC as well as adnexal tumors.Data Acquisition
We retrospectively assessed the following clinical and outcome
variables: gender, age at first diagnosis, comorbidities, primary tumor
site, primary tumor, regional lymph node involvement, distant
metastatic spread classification (according to 7th edition of the Union
Internationale Contre le Cancer for skin cancers), R classification
(resection status: R0 = negative margins, R1 = microscopically positive
margins, R2 = macroscopically positive margins), number of operations
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preexisting skin damage [chronic actinic damage (CAD), scar, and
radioderm], local relapse (LR, yes/no), occurrence of regional lymph
node metastasis (LNM, yes/no), DM (yes/no), and PFS.
Furthermore, we analyzed the following histopathologic characteris-
tics: tumor depth (TD), according to Breslow (in mm); maximal vertical
infiltration (MVI, S = superficial: dermis, M = medium: subcutis, D =
deep: fascia, muscle, cartilage, or bone); vessel invasion (VI, yes/no);
muscle invasion (MI, yes/no); and bone infiltration (BI, yes/no).
Statistical Analysis
All statistical analyses were performed by a statistician using the
Statistical Package for Social Sciences, version 18.0 (SPSS Inc,
Chicago, IL). Significance was defined as the probability of type one
error of b5% (P b .05).
Categorical variables were analyzed using the chi-square test and
Fisher exact test. For continuous variables, the Mann-Whitney U test
was used as a non-parametric test for abnormally distributed variablesTable 1. Demographic and Clinical Characteristics of the Study Population with regard to Nodal
Disease (LNM)
Parameter LNM Significance
(P Value)
No Yes
Gender (1.000)
Male n (%) 52 (94.5) 3 (5.5)
Female n (%) 32 (94.1) 2 (5.9)
Age (.776)
Mean Years 71.7 72.4
SD Years 12.7 9.2
Comorbidities
Immunosuppression (yes/no) n 1/83 0/5 (1.000)
Renal insufficiency (yes/no) n 7/77 1/4 (.383)
Cardiovascular disease n 14 2 (.187)
Diabetes mellitus n 7 – (1.000)
Thyroidal disease n 3 – (1.000)
Primary tumor site (.004) **
Nose n (%) 27 (96.4) 1 (3.6)
Ear and periauricular n (%) 16 (88.9) 2 (11.1)
Scalp and forehead n (%) 12 (100.0) (0.0)
Periorbital/eyelids n (%) 9 (100.0) (0.0)
Cheek n (%) 8 (100.0) (0.0)
Perioral/lips n (%) 6 (85.7) 1 (14.3)
Neck n (%) 6 (100.0) (0.0)
More than one region n (%) (0.0) 1 (100.0)
pT classification (.097)
pT1 n (%) 54 (98.2) 1 (1.8)
pT2 n (%) 15 (93.8) 1 (6.3)
pT3 n (%) 12 (85.7) 2 (14.3)
pT4 n (%) 3 (75.0) 1 (25.0)
Skin damage (.908)
CAD n (%) 22 (95.7) 1 (4.3)
Scar n (%) 8 (100.0) (0.0)
CAD and scar n (%) 2 (100.0) (0.0)
Radioderm n (%) 1 (100.0) (0.0)
None n (%) 51 (92.7) 4 (7.3)
R classification (resection status) (.017) *
R0 (in sano) n (%) 75 (97.4) 2 (2.6)
R1/R2 (non in sano) n (%) 9 (75.0) 3 (25.0)
Resection number (.379)
Mean 1.5 1.6
SD 0.8 0.5
Median 1 2
PFS time (b .001) ***
Mean Months 154.2 16.1
95% CI Months 147.8-160.6 8.1-24.1
* P b .05.
** P b .01.
*** P b .001.(age), and an independent t test was used to analyze normally
distributed variables (TD). PFS was defined as the time from first
diagnosis to local relapse or nodal or distant dissemination, and the
data on patients without these events were censored for the last
follow-up period. PFS was calculated using the Kaplan-Meier
method, and group differences were analyzed using the log-rank test.
Results
The mean age at first diagnosis was 71.8 years (median 74.1, SD 12.5,
range 23.8-92.6). The most common primary tumor site was the nose
(31.5%), followed by the ear and periauricular region (20.2%), the
forehead and scalp (13.5%), the periorbital region (10.1%), the cheek
(9.0%), the lips and perioral region (7.9%), and the neck (6.7%). In
one case of a tumor that extended over several anatomic regions, the
region of first onset was indeterminable. The mean follow-up time
was 47.7 months (SD 26.9, range 12-112). We observed local relapse in
four patients (4.5%). Five patients (5.6%) developed LNM (one initial
nodal disease and four during follow-up), of these two (2.2%) experienced
distant dissemination and tumor-dependent death. Seven patients (7.9%)
developed disease progression (local relapse, nodal or distant dissemina-
tion), resulting in a mean PFS time of 147.4 months [95% confidence
interval (CI): 138.4-156.3] for the total study population.
The characteristics of the study population with regard to nodal
disease are shown in Table 1. The analysis of differences between
patients with and without LNM revealed that increased TD (P =
.002), localization at the ear or periauricular region (P = .004), MVI
(P = .008), resection status [R0 vs R1/R2: P = .017, OR (odds ratio) =
12.3 (95% CI: 1.8-83.9)], MI [P = .026, OR = 9.9 (95% CI:
1.5-66.4)], VI [P = .032, OR = 9.0 (95% CI: 1.4-59.6)], and pT
classification [T1/T2 vs T3/T4: P = .054, OR = 6.9 (95% CI:
1.1-44.9)] were associated with increased risk for nodal disease.
Patients with local relapse had VI, MI, BI, and advanced T
classification of T3 or T4 significantly more often than patients
without local relapse (all P b .001). Furthermore, MVI (P = .001),
TD (P = .009), and R classification (P = .029) showed significant
associations with local tumor recurrence.Figure 2. PFS with regard to maximal vertical invasion (MVI) of BSC
of the head and neck (BSC-HN). BSC-HN patients with deep MVI
had significantly more unfavorable outcomes, as indicated by PFS,
compared to patients with medium MVI (P = .010) and superficial
MVI (P b .001). The difference in PFS between patients with
superficial MVI and medium MVI was not significant (P = .252).
Figure 3. PFS with regard to pT classification of BSC-HN. Patients
with advanced BSC-HN with pT4 classification had significantly
shorter PFS than those with pT3 (P= .024), pT2 (P= .001), and pT1
(P b .001) classifications. The unfavorable outcome rate, indicated
by PFS, was significantly greater for BSC-HN cases classified as
pT3 than for those classified as pT1 (P = .026); however,
differences between BSC-HN cases classified as pT3 and pT2
(P = .307) and between those classified as pT2 and pT1 (P = .397)
were not significant.
Table 2. Histologic Features of the Study Population with regard to Nodal Disease (LNM)
Parameter LNM Significance
(P Value)
No Yes
Ulceration (.658)
No n (%) 46 (95.8) 2 (4.2)
Yes n (%) 38 (92.7) 3 (7.3)
TD (.002) **
Mean mm 3.5 14.0
SD mm 2.9 6.0
95% CI mm 2.9-4.2 6.6-21.4
Maximal vertical infiltration (MVI) (.008) **
Superficial n (%) 29 (96.7) 1 (3.3)
Medium n (%) 38 (100.0) (0.0)
Deep n (%) 17 (81.0) 4 (19.0)
Vessel invasion (VI) (.032) *
No n (%) 72 (97.3) 2 (2.7)
Yes n (%) 12 (75.0) 3 (25.0)
Muscle invasion (MI) (.026) *
No n (%) 73 (97.3) 2 (2.7)
Yes n (%) 11 (78.6) 3 (21.4)
Bone infiltration (BI) (.095)
No n (%) 76 (96.2) 3 (3.8)
Yes n (%) 8 (80.0) 2 (20.0)
* P b .05.
** P b .01.
*** P b .001.
able 3. Overview of the Studies Presenting Data Concerning Metastatic BSC
uthor (Year) Patients
[n (%)]
LNM
[n (%)]
DM
[n (%)]
Total (LNM + DM)
[n (%)]
etti et al. (2003) [5] 35 n.s. 1 (2.9) 1 (2.9)
orel et al. (1973) [27] 35 n.s. 3 (8.6) 3 (8.6)
owman et al. (2003) [7] 27 n.s. 2 (7.4) 2 (7.4)
eibovitch et al. (2005) *[8] 98 2 (2.0) (0.0) 2 (2.0)
artin et al. (2000) [2] 28 5 (17.9) 1 (3.6) 5 (17.9)
chuller et al. (1979) [25] 33 n.s. 2 (6.1) 2 (6.1)
karia (2010) [19] 56 (0.0) (0.0) (0.0)
ermker et al. (2014) 89 5 (5.6) 2 (2.2) 5 (5.6)
otal LNM 271 12 (4.4)
otal DM 401 11 (2.7)
otal LNM + DM 401 20 (5.0)
.s. = not specified.
* Leibovitch et al. [8] presented in total 178 BSC cases, but data concerning metastasization were only
ublished for 98 patients who completed a 5-year follow-up period.
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significant associations with PFS time. Figures 2 and 3 illustrate the
associations of PFS time with MVI and T classification.
Discussion
Due to its rare occurrence, diagnostics including immunohistochem-
istry, therapy, and prognostic prediction for BSC, especially BSC-HN,
remain controversial [5,18,22,24]. Due to increasing incidence of
non-melanoma skin cancer, the incidence of BSC can be expected to
rise, and clinicians and researchers need valuable data for improving the
management of these patients.Most BSCs arise in the head and neck, so
our study provides important insights into this tumor entity. Our study
included 89 patients, constituting one of the largest cohorts in
published studies of BSC, and our study specifically included only
primary BSC-HNcases.Only Leibovitch et al. presented follow-up data
for a larger BSC sample (n = 98) [8]. In terms of gender and age
distribution and primary tumor location, our results are in line with
those published previously [1,2,5,7–9,12,25–27].
As in most tumor entities of the head and neck, crucial events for
unfavorable outcomes with limited PFS and disease specific survival
include local tumor relapse, occurrence of nodal metastases, and
distant dissemination. In BSC, possible parameters of prognostic
relevance for these events and PFS have not been sufficiently
analyzed before.
In our study, we observed a low local recurrence rate of only 4.5%
(n = 4), which can be attributed to the usage of histographic Mohs
tumor resection. Older studies that did not use histographic controlled
Mohs tumor resection presented recurrence frequencies between 12%
and 51% [25,27]. Performing histographic surgery (Mohs micrographic
surgery) diminishes this rate to 4% to 9% [8,19,24]. As described
previously, incomplete tumor excision (R classification), TD, and tumor
size (T classification) influenced local relapse in the current study.
Furthermore, we found significant associations between local recurrence
and maximal vertical infiltration (MVI), BI, muscle invasion (MI), and
VI. These parameters had not been explicitly analyzed by previous studies.BSC has a much higher potential to metastasize than BCC and the
dissemination rate for BSC is more similar to that of cutaneous SCC
(cSCC) [5,22]. While histologic and immunohistochemical charac-
teristics (especially the expression of BerEP4 and epithelial membrane
antigen) showed similarities between BSC and BCC, the biologic
behavior and aggressiveness of BSC are more comparable to cSCC.
Only a few studies have systematically analyzed nodal and distant
dissemination within a defined follow-up period. Table 2 summarizes
currently available data on this topic. Nodal metastases occurred in
4.4% of all BSC patients and the risk of DM was approximately
2.5%. No study had evaluated potential risk factors for LNM
previously. This study was the first that analyzed associations between
MVI, BI, MI, and VI and nodal disease in BSC and was the first to
show a significant association between these parameters, T and R
classification, TD, and localization at the ear and LNM. Our results
may help define BSC-HN patients with high risk of metastasis in the
future. In these high-risk cases, elective surgical lymph nodeT
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Yoshida et al. [28], or elective lymph node dissection), intensified
follow-up care, including ultrasonography and radiologic assessments
(computed tomography, magnetic resonance imaging), and even
adjuvant therapies, such as irradiation of the lymph drainage area, can
be considered. The presently available data do not allow for the
definition and evaluation of a well-defined lymph node management
protocol; thus, further prospective studies are necessary (Table 3).
Some limitations of this study should be considered. Due to the
rarity of this tumor entity, the number of patients included in this
study was relatively small, especially within even smaller subgroups.
Furthermore, the retrospective nature of our analysis generates the
risks of poor data quality and selection bias due to monocentricity. In
contrast, the strength of our analysis was that we presented a
well-defined and relatively homogeneous sample of BSC cases in the
head and neck area.
Conclusion
While the histologic characteristics of BSC tend to define it as a
subtype of BCC, its biologic and clinical behaviors suggest that BSC
is its own type of skin cancer with disease courses similar to cSCC.
Risk factors for LNM are of special interest for the management of
BSC-HN patients. In particular, incomplete tumor resection (R
classification), increased tumor size (T classification), TD, maximal
vertical infiltration, muscle invasion, and VI indicate a higher risk for
LNM in BSC-HN.
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